A Study to Access the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

Recruiting

Phase 3

A Study to Access the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)A Study to Access the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

Sponsor:

Axsome Therapeutics, Inc.

Code:

NCT05972044

Conditions

ADHD

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Solriamfetol 150 mg

Solriamfetol 300 mg

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information